Analyst Price Target is $59.14
▲ +238.54% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $59.14, with a high forecast of $95.00 and a low forecast of $33.00. The average price target represents a 238.54% upside from the last price of $17.47.
Current Consensus is
The current consensus among 7 contributing investment analysts is to buy stock in 89bio.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.